In this study, we used small interfering RNA (siRNA) directed against vascular endothelial growth factor receptor 1 (vegfr1) mRNA to investigate the role of VEGFR1 in ocular neovascularization (NV). After evaluating many siRNAs, Sirna-027 was identified; it cleaved vegfr1 mRNA at the predicted site and reduced its levels in cultured endothelial cells and in mouse models of retinal and choroidal neovascularization (CNV). Compared to injection of an inverted control sequence, quantitative reverse transcriptase-PCR demonstrated statistically significant reductions of 57 and 40% in vegfr1 mRNA after intravitreous or periocular injection of Sirna-027, respectively. Staining showed uptake of 5-bromodeoxyuridine-labeled Sirna-027 in retinal cells that lasted between 3 and 5 days after intravitreous injection and was still present 5 days after periocular injection. In a CNV model, intravitreous or periocular injections of Sirna-027 resulted in significant reductions in the area of NV ranging from 45 to 66%. In mice with ischemic retinopathy, intravitreous injection of 1.0 mg of Sirna-027 reduced retinal NV by 32% compared to fellow eyes treated with 1.0 mg of inverted control siRNA. These data suggest that VEGFR1 plays an important role in the development of retinal and CNV and that targeting vegfr1 mRNA with siRNA has therapeutic potential. Gene Therapy (2006) 13, 225-234.
Introduction
Vascular endothelial growth factor (VEGF-A) plays a central role in the development of several types of neovascularization (NV), including retinal and choroidal neovascularization (CNV). [1] [2] [3] [4] These data suggest that the VEGF pathway may be an important therapeutic target and results from clinical trials using an aptamer 5 or an antibody fragment 6 that binds VEGF-A have supported this contention. Blocking VEGF receptors is another strategy for antagonizing VEGF-A that has the potential advantage of blocking multiple VEGF family members at once.
There are multiple VEGF receptors (VEGFR) and their role in angiogenesis is not completely clear. Mutated VEGFs that bind VEGFR2, but not VEGFR1, have full activity as stimulators of endothelial cell proliferation and migration, and stimulate corneal angiogenesis and vascular leakage in skin, whereas VEGFs that bind VEGFR1, but not VEGFR2, lack these activities. 7 Therefore, for endothelial cells in vitro, and for cornea and skin in vivo, VEGFR2 is essential for VEGF-mediated activity. In fact, it has been postulated that VEGFR1 is a decoy receptor that negatively regulates the activity of VEGFR2, 8 and during developmental angiogenesis this appears to be the case, because vegfr1 À/À mice show excessive proliferation of angioblasts, a sign of VEGF-A overaction. 9 However, in other settings, VEGFR1 appears to play proangiogenic and propermeability roles, effects that may be mediated by placental growth factor (PlGF), which binds VEGFR1, but not VEGFR2. 10 Also, stimulation of VEGFR1 may cause vascular endothelium in some vascular beds to release tissue-specific growth factors. 11 Therefore, investigations in the vascular bed of interest must be carried out to determine the roles of VEGFR1 and VEGFR2 in particular disease processes.
Small interfering RNAs (siRNAs) provide a useful means to selectively reduce mRNAs and probe the function of gene products. In this study, we used Sirna-027, an siRNA that specifically reduces vegfr1 mRNA, to explore the role of VEGFR1 in ocular NV.
Results

siRNA-mediated reduction of vegfr1 mRNA in cultured cells
Candidate siRNAs targeting vegfr1 mRNA were designed using a bioinformatics-based approach with one selection criterion being conservation of the siRNA target site in the human, mouse, and rat vegfr1 sequences. This constraint supports direct animal testing of siRNAs that are also suitable for human clinical trials. Chemical modifications of the siRNA were included that enhance stability and support their use in vivo. These include inverted abasic moieties at the 5 0 and 3 0 ends of the sense strand oligonucleotide and a single phosphorothioate linkage between the last two nucleotides at the 3 0 end of the target-complementary (antisense) strand. These modifications significantly extend the in vivo half-life in vitreous and ocular tissue following intraocular injection into rabbit eye (manuscript in preparation).
The lead candidate Sirna-027 was first identified from a panel of stabilized siRNAs by its ability to reduce NV in a rat corneal pocket model of VEGF-induced angiogenesis (data not shown). To determine if treatment with Sirna-027 specifically reduced its endogenous target mRNA, cell culture studies were carried out in human aortic endothelial cells (HAECs). When quantified by reverse transcriptase (RT)-PCR, cellular levels of vegfr1 mRNA were reduced by 71% following treatment with 12.5 nM Sirna-027 relative to treatment with the inverted control siRNA (Figure 1a) . No effect of Sirna-027 was noted on the level of vegfr2 mRNA (Figure 1b ). While these two VEGF receptors share considerable homology, the Sirna-027 target site is not present in vegfr2 mRNA. Significant reduction of vegfr1 mRNA and lack of activity on vegfr2 mRNA support the specificity of Sirna-027 cleavage.
The potency of Sirna-027 was evaluated using a luciferase-reporter assay in cultured HeLa cells. A reporter plasmid was constructed by ligating B80 nucleotides of human vegfr1 sequence into the 3 0 untranslated region of the Renilla luciferase gene. The reporter plasmid also contained a Firefly luciferase gene for use as a normalization control. When this reporter plasmid and Sirna-027 were cotransfected into HeLa cells, RNAi activity directed against the vegfr1 target appended to the Renilla mRNA resulted in a reduction of Renilla luciferase activity. As shown in Figure 1c , the IC 50 for Sirna-027 in this system is B50 pM. The dose-response curve reaches saturation at approximately 1 nM Sirna-027 with a 495% reduction in the ratio of Renilla:Firefly luciferase activity. These data demonstrate that Sirna-027 is effective at extremely low concentrations.
Experiments in a HeLa cell extract confirmed that Sirna-027 acts by an RNAi mechanism to direct cleavage of vegfr1 sequence at the expected site. The site of siRNAdirected target cleavage is defined by the 5 0 end of the siRNA antisense strand and results in site-specific strand scission between the target nucleotides annealed to the 10th and 11th positions of the target complementary sequence. 12 As shown in Figure 2 , incubation of an B100 nucleotide 5 0 -32 P-labeled transcript of vegfr1 sequence with Sirna-027 in a HeLa cell extract resulted in specific cleavage predominantly at the expected position. The amount of product formed increased with time; after 2 h approximately 25% of the target RNA was converted to product. No cleaved product was observed when the target was incubated with a control siRNA with the same stabilizing modifications. Thus, Sirna-027 acts via an RNAi mechanism and directs the site-specific cleavage of vegfr1 mRNA.
Intravitreous or periocular injection of Sirna-027 significantly reduces vegfr1 mRNA and protein in the eye Experiments were designed to determine how effectively Sirna-027 is able to reduce expression of vegfr1 mRNA in two mouse models of ocular NV. In a mouse model of Figure 1 Sirna-027 specifically reduces vegfr1 mRNA. Cultured HAECs were left untreated or transfected with LF2K complexes containing 12.5 nM Sirna-027 or the inverted control siRNA. Total RNA isolated at 24 h post-transfection was analyzed by RT-PCR for either vegfr1 (a) or vegfr2 (b) mRNA. Normalized RNA levels for the untreated samples were set to 1 to facilitate comparison. Treatment with Sirna-027 reduced the level of vegfr1 by 71% (P ¼ 0.0001) compared to treatment with the inverted control siRNA, but had no effect on the level of vegfr2. Note that in this cell culture system siRNA transfection conditions alone significantly increased the level of both VEGF receptor mRNAs. Compared to untreated cells, treatment with the inverted control resulted in a 40-75% increase in vegfr1 (P ¼ 0.0026) and vegfr2 (P ¼ 0.0038), respectively. As this effect is likely due to the use of the lipid transfection agent, it is appropriate to state the activity of Sirna-027 relative to treatment with the inverted control siRNA. (c) A dose-response curve (5-5000 pM) for Sirna-027 was obtained in a luciferase reporter system in HeLa cells in which cleavage at the Sirna-027 target site resulted in decreased Renilla luciferase activity (normalized to activity of Firefly luciferase located on the same plasmid reporter). Curve fit of the data using Kaleidograph software (Synergy Software, Reading, PA, USA) revealed an IC 50 of B50 pM. For (a-c), means (+s.e.m.) were calculated from three replicate transfections. A similar study was carried out in mice with oxygeninduced ischemic retinopathy. In this case, mice were given an intravitreous injection of 3 mg of Sirna-027 in one eye and 3 mg of inverted control siRNA in the other eye at P12, the beginning of the ischemic period. At P15, real-time PCR demonstrated that injection of Sirna-027 resulted in a 57% reduction in vegfr1 mRNA (Figure 3b ) compared to intravitreous injection of inverted control siRNA. Periocular injection of Sirna-027 also significantly reduced the level of vegfr1 mRNA in the retinas of mice with ischemic retinopathy (Figure 3c ). Periocular injection of 7.5 mg of Sirna-027 at P12, P14, and P16 resulted in Figure 2 Sirna-027 directs site-specific cleavage of target vegfr1 RNA. A radiolabeled transcript of vegfr1 RNA sequence containing the Sirna-027 target site was generated for use as the substrate for an siRNA-induced cleavage assay in HeLa cell extract. The sequence of the Sirna-027 target site is shown to the left of RNA markers generated from the radiolabeled transcript by alkaline hydrolysis (lane 1, nucleotide ladder) or RNAse T1 (lane 2, digestion at guanosine residues). The remaining lanes contain products following a 2 h incubation with either the negative control siRNA (lane 3, no cleavage products) or Sirna-027 for 30, 60, 90, and 120 min (lanes 4-7, respectively). The predominant Sirna-027 cleavage product is observed at the expected location within the substrate as indicated with A k A in the sequence. Secondary products, one or more nucleotides shorter, may result from substrate heterogeneity or target RNA degradation prior to or subsequent to cleavage. (a) On day 1, Bruch's membrane was ruptured at three locations in each eye and PBS, 1.5 mg Sirna-027 or 1.5 mg inverted control siRNA was introduced by intravitreous injection. After 7 days mice were euthanized, eyes were removed, and total RNA was prepared. A faint band for vegfr1 mRNA was visualized after amplification of RNA isolated from eyes injected with Sirna-027 (lane 1), compared to more prominent bands amplified from RNA isolated from eyes injected with inverted siRNA (lane 2) or PBS (lane 3). Amplification of ribosomal S16 mRNA from the same samples demonstrates that the low level of vegfr1 mRNA in lane 1 is not due to a difference in total RNA used for PCR reactions. (b) Following 5 days in 75% oxygen, mice at P12 were returned to room air and given an intravitreous injection of 3 mg Sirna-027 or inverted control siRNA. At P15, total retinal RNA was isolated and RT-PCR was performed using primers specific for vegfr1 or cyclophilin mRNA. Bars represent the mean (+s.e.m.) vegfr1 mRNA copy number per 10 6 copies of cyclophilin A mRNA and show a 57% reduction (P ¼ 0.004) in vegfr1 mRNA in eyes injected with Sirna-027 (n ¼ 8) compared to eyes injected with inverted siRNA (n ¼ 7). (c) Mice with ischemic retinopathy induced as described in (b) were given a periocular injection of 7.5 mg of Sirna-027 or inverted siRNA at P12, P14 and P16. At P17, vegfr1 mRNA was measured as described in (b). There was a 40% reduction (P ¼ 0.0121) of vegfr1 mRNA in retinas of eyes injected with Sirna-027 (n ¼ 9) compared to those injected with inverted control siRNA (n ¼ 6). Bars represent the mean (+s.e.m.) vegfr1 mRNA copy number per 10 6 copies of cyclophilin A mRNA. (d) Mice with ischemic retinopathy induced as described in (b) were given an intravitreous injection of 5 mg Sirna-027 or inverted control siRNA at P12. At P15, mice were euthanized and VEGFR1 was measured by ELISA in retinal homogenates. There was a 30% reduction (P ¼ 0.0103) of VEGFR1 protein in eyes injected with Sirna-027 (n ¼ 8) compared to eyes injected with inverted control siRNA (n ¼ 7). Data are expressed as mean levels of VEGFR1 protein (+s.e.m.).
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To assess the impact on VEGFR1 protein levels, P12 mice with ischemic retinopathy were given an intravitreous injection of 5 mg of Sirna-027 in one eye and 5 mg of inverted control siRNA in the other eye. At P15, ELISA results showed that the level of VEGFR1 in the retinas of Sirna-027-treated eyes was reduced by 30% compared to retinas of eyes injected with inverted control siRNA ( Figure 3d ).
Distribution of siRNA in the eye at several time points after intravitreous or periocular injection 5-Bromodeoxyuridine (BrdU)-labeled Sirna-027 was used to evaluate distribution of siRNA in the mouse eye over time after injection. 6 h after intravitreous injection of 5 mg of BrdU-labeled Sirna-027, there was staining for BrdU in ganglion cells, some cells in the inner nuclear layer, and a strip along the external limiting membrane (Figure 4 ). At 12 and 24 h after injection, most of the staining was in the ganglion cells and inner nuclear layer. By 48 h, there is also prominent staining in photoreceptors. At 5 days after injection, it appeared that most of the BrdU-labeled siRNA had been cleared from the retina.
At 6 h after periocular injection of 25 mg of BrdUlabeled Sirna-027, there was staining of some ganglion cells, a few cells in the inner nuclear layer, and the region of the external limiting membrane ( Figure 5 ). The staining in ganglion cells, the inner nuclear layer, and the strip along the external limiting membrane increased at 12 h, seemed to peak at 24 h, and decreased at later time points although it was still detectable at 5 days after injection. The staining in photoreceptor cell bodies peaked at 12-24 h and was back to baseline by 72 h. These results demonstrate that siRNAs rapidly access all layers of the retina after either intravitreous or periocular injection and are detectable for several days after injection.
Intravitreous or periocular injection of Sirna-027 suppresses CNV
The effect of Sirna-027 in vivo was assessed using a laserinduced model of CNV in adult female C57BL/6 mice. One group of mice was treated on days 1 and 7 with an intravitreous injection of 1.5 mg of Sirna-027 in one eye and 1.5 mg of inverted control siRNA in the fellow eye. A second group of mice received injection of 0.5 mg of Sirna-027 in one eye and PBS in the fellow eye on days 1 and 7. At 14 days after rupture of Bruch's membrane, eyes that received intraocular injections of inverted siRNA or PBS developed large areas of CNV (Figure 6a and b). Compared to the control eyes, eyes treated with 1.5 or 0.5 mg of Sirna-027 had significantly smaller areas of CNV (Figure 6c-e) . Reductions in CNV lesion size of 56 and 66% vs 1.5 mg inverted control siRNA or PBS, respectively, were noted. Figure 4 Distribution of BrdU-labeled Sirna-027 in the retina at various times after intravitreous injection. In all, 5 mg of BrdUlabeled Sirna-027 was injected into the vitreous cavity of mice and, at 6, 12, 24, or 48 h (h) or 5 days after injection, mice were euthanized and ocular frozen sections were immunohistochemically stained for BrdU. At 6 h after injection, staining was limited to ganglion cells, a few cells in the inner nuclear layer, and the region of the external limiting membrane. At 12 and 24 h after injection, there was strong staining in ganglion cells and the inner nuclear layer. At 48 h and beyond, there was no longer staining in ganglion cells. There was widespread strong staining in photoreceptor cell bodies at 48 h that was less at earlier and later time points. By 5 days after injection, there was no longer staining for BrdU in the retina. GCL ¼ ganglion cell layer; INL ¼ inner nuclear layer; ONL ¼ outer nuclear layer. Figure 5 Distribution of BrdU-labeled Sirna-027 in the retina at various times after periocular injection. In all, 5 ml containing 25 mg of BrdU-labeled Sirna-027 was injected into the periocular space of mice and, at 6, 12, 24, or 48 h (h) or 5 days after injection, mice were euthanized and ocular frozen sections were immunohistochemically stained for BrdU. At 6 h after injection, staining was limited to ganglion cells, a few cells in the inner nuclear layer, and the region of the external limiting membrane. The staining in ganglion cells, the inner nuclear layer, and the strip along the external limiting membrane increased at 12 h, seemed to peak at 24 h, and decreased at later time points although it was still detectable at 5 days after injection. The staining in photoreceptor cell bodies peaked at 12-24 h and was back to baseline by 72 h. GCL ¼ ganglion cell layer; INL ¼ inner nuclear layer; ONL ¼ outer nuclear layer.
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The effect of periocular injections of Sirna-027 was also investigated. After rupture of Bruch's membrane, mice were given 5 ml containing 7.5 mg of either Sirna-027 or inverted control siRNA every 3 days for 2 weeks by periocular injection. Eyes treated with Sirna-027 had significantly smaller areas of CNV compared to those treated with inverted siRNA (Figure 7 ). CNV area was reduced by 45%.
Intravitreous injection of Sirna-027 suppresses retinal NV
The effect of Sirna-027 on NV was also assessed in a model of ischemia-induced retinal NV. In this model, areas of retinal ischemia due to closure of retinal blood vessels result in sprouting of new vessels that grow through the internal limiting membrane into the vitreous cavity, similar to the situation seen in humans with retinopathy of prematurity or proliferative diabetic retinopathy. Mice with ischemic retinopathy were given an intravitreous injection of 1 ml containing 1 mg of Sirna-027 in one eye and inverted control siRNA in the fellow eye at P12. At P17, the amount of retinal NV was significantly reduced in eyes injected with Sirna-027 compared to those injected with inverted siRNA ( Figure  8 ). Following this single injection, the area of retinal NV was reduced by 32%.
Discussion
Several lines of evidence suggest that VEGFR2 plays a primary role in VEGF signaling, but the action of VEGFR1 is less established and appears to be contextdependent. During developmental angiogenesis, VEGFR1 acts as a negative regulator of VEGF activity, 13 but in adult mice with Lewis lung carcinoma, tumor Figure 6 Intravitreous injection of Sirna-027 suppresses choroidal NV. Ruptures in Bruch's membrane were induced at three locations in each eye on day 1. On days 1 and 7, mice received a 1 ml intravitreous injection of 1.5 mg Sirna-027 in one eye and 1.5 mg inverted control siRNA in the fellow eye, or 0.5 mg Sirna-027 in one eye and PBS in the fellow eye. On day 14, mice were perfused with fluorescein-labeled dextran and choroidal flat mounts were examined by fluorescence microscopy. There were large areas of choroidal NV at Bruch's membrane rupture sites in eyes injected with 1.5 mg inverted control siRNA (a) or PBS (b), while eyes injected with 0.5 mg (c) or 1.5 mg of Sirna-027 (d) had small areas of choroidal NV. Measurement of the area of choroidal NV by image analysis (e) demonstrated that eyes injected with Sirna-027 had significantly smaller choroidal NV areas than fellow eye controls. Data are expressed as the averaged CNV area (+s.e.m.). (P ¼ 0.020 for difference between 1.5 mg Sirna-027 (n ¼ 6) and 1.5 mg inverted control siRNA (n ¼ 16), P ¼ 0.011 for difference between 0.5 mg Sirna-027 (n ¼ 5) and PBS (n ¼ 5)).
Knockdown of
14 Also, inhibition of VEGFR1 with an anti-VEGFR1 antibody suppressed ischemia-induced retinal NV. 10 Moreover, some proangiogenic effects may be mediated by PlGF specifically through VEGFR1 and not VEGFR2. 10 In this study, we used Sirna-027, a chemically stabilized siRNA directed against vegfr1 mRNA, to reduce specifically the levels of retinal VEGFR1. Either intravitreous or periocular injection of Sirna-027 caused significant reduction of vegfr1 mRNA and significantly suppressed CNV or retinal NV; therefore, VEGFR1 is a positive regulator of both CNV and retinal NV.
In addition to VEGFR1 and VEGFR2, the neuropilins (Npns), Npn1 and Npn2, participate in VEGF signaling and both play important roles in pathologic ocular NV. [15] [16] [17] [18] Intravitreous injection of an anti-Npn1 antibody suppresses ischemia-induced retinal NV and mice deficient in Npn2 have markedly reduced ischemia-induced and VEGF-induced retinal NV. Thus, it appears that all four VEGF receptors, VEGFR1, VEGFR2, Npn1, and Npn2, play important nonoverlapping roles in pathologic ocular NV, and each provides a target for therapeutic intervention.
In addition to demonstrating that VEGFR1 is a potential target for treatment of CNV, this study also suggests that a viable strategy for attacking that target is to knock down vegfr1 mRNA with Sirna-027. Labeled Sirna-027 was detected in the retina for 4-5 days following intravitreous injection, suggesting that it is taken up and retained within retinal cells for a substantial period of time. After periocular injection, labeled Sirna-027 was able to pass through the sclera and choroid and was detectable within retinal cells for at least 5 days. With either route of delivery, there was sufficient reduction of vegfr1 mRNA to significantly suppress CNV. Also, intravitreous injection of Sirna-027 significantly suppressed ischemia-induced retinal NV, with corresponding reductions in vegfr1 mRNA and protein. These data suggest that both intravitreous and periocular Figure 7 Periocular injection of Sirna-027 suppresses choroidal NV. Bruch's membrane was ruptured at three locations in each eye on day 1. On days 1, 4, 7, 10, and 13, mice received periocular injections of 7.5 mg of Sirna-027 or inverted control siRNA. On day 14, mice were perfused with fluorescein-labeled dextran and choroidal flat mounts were examined by fluorescence microscopy. There were large areas of choroidal NV at Bruch's membrane rupture sites in eyes injected with inverted siRNA (a), while eye injected with Sirna-027 had smaller areas of choroidal NV (b). Measurement of the area of choroidal NV by image analysis (c) demonstrated that, compared to the area of choroidal NV at Bruch's membrane rupture sites (n ¼ 13) in eyes injected with inverted siRNA, there was a 45% reduction in the area of choroidal NV at rupture sites (n ¼ 12) in eyes treated with Sirna-027 (P ¼ 0.0002). Data are expressed as the averaged CNV area (+s.e.m.). Figure 8 Sirna-027 reduces retinal NV in mice with oxygeninduced ischemic retinopathy. Litters of neonatal C57BL/6 mice were placed in 75% oxygen at P7. At P12, mice were removed to room air and were given an intravitreous injection of 1 mg of Sirna-027 or inverted control siRNA. At P17, the mice were euthanized and ocular frozen sections were stained with GSA. Mice treated with inverted siRNA (n ¼ 8) showed extensive preretinal NV (a, arrows). However, mice treated with Sirna-027 (n ¼ 8; b, arrows) had significantly less preretinal NV. (c) Data are represented as the average NV area (+s.e.m.) and demonstrated that Sirna-027 treatment reduced preretinal NV by 32% relative to treatment with inverted control (P ¼ 0.0008).
Knockdown of vegfr1 mRNA inhibits ocular neovascularization J Shen et al injection of Sirna-027 deserve further testing as potential treatment approaches for ocular NV. Previous studies have demonstrated that VEGF is a critical stimulus for CNV and an important therapeutic target. Two VEGF antagonists, an aptamer and an antibody fragment, reduce vision loss in patients with CNV when given by repeated intravitreous injections. 5, 6 Identifying additional VEGF pathway antagonists with improved characteristics, such as a prolonged duration of effect or a less-invasive route of delivery, is an important goal. The ability to reduce more than one target in a pathway may be especially useful and could be accomplished using bi-or multifunctional siRNAs designed to target more than one mRNA. Thus, the identification and use of chemically stabilized siRNAs that can specifically target one or more members of the VEGF pathway may be a viable alternative, or an adjunct, to more traditional therapeutic approaches. A phase I clinical trial investigating the safety of a single intravitreous injection of several different doses of Sirna-027 in patients with neovascular age-related macular degeneration is underway. The effect of a single intravitreous injection may be too brief to achieve a sustained therapeutic effect; so, if the safety profile for Sirna-027 is good, it is planned to perform a phase II trial to investigate the efficacy of multiple intravitreous injections of Sirna-027 in patients with neovascular AMD. Additional preclinical studies are also needed to investigate strategies for sustained delivery of siRNAs to the eye, which would not only be useful for treatment with Sirna-027 but also could be the basis for using siRNAs to treat a variety of ocular disorders in the future. siRNA synthesis and structure RNA single strands were synthesized at Sirna Therapeutics, Inc. by standard procedures. 19 Complementary sense and antisense single strands were annealed, desalted, and lyophilized to provide the final siRNA duplex. The integrity and purity of the siRNA was confirmed by HPLC, and MALDI-TOF MS methodologies. Lyophilized duplex was reconstituted in PBS.
Materials and methods
The sequences of the two oligonucleotide strands of the Sirna-027 siRNA duplex are as follows: sense, 5 0 -BCU GAG UUU AAA AGG CAC CCT TB-3 0 ; antisense, 5 0 -GGG UGC CUU UUA AAC UCA GT S T-3 0 . Modifications are unpaired deoxythymidines (T), one phosphorothioate linkage (s) and two inverted 2 0 -deoxy abasic nucleotides (B). 20 The sense strand is identical in sequence to the target site in vegfr1 mRNA; the antisense strand directs cleavage of vegfr1 mRNA when bound in the RNA-induced silencing complex (RISC). The Sirna-027 target sequence is present in vegfr1 mRNA for human (GenBank accession no. NM_002019.1, nucleotides 349-368), mouse (NM_010228.1), rat (NM_019306.1), as well as in the pig and monkey vegfr1 genes. RNA was isolated from pig and monkey tissue and used to synthesize cDNA for vegfr1, which was sequenced to confirm the presence of the Sirna-027 target site. A negative control siRNA with the same stabilizing modifications as Sirna-027 was used. This inverted control is an siRNA with an inverted Sirna-027 sequence as follows: sense, 5 0 -BCC CAC GGA AAA UUU GAG UCT TB-3 0 ; antisense, 5 0 -GAC UCA AAU UUU CCG UGG GTsT-3 0 .
BrdU labeling
A single BrdU nucleotide was introduced at the 3 0 -end of the antisense strand replacing the penultimate nucleotide. BrdU-labeled Sirna-027 was made by annealing this antisense strand with its complementary sense strand to form the duplex.
Measurement of vegfr1 mRNA in Sirna-027-treated HAECs
HAECs (Cambrex Corp., East Rutherford, NJ, USA) were seeded in the 24 inner wells of 48-well plates and grown to 60-75% confluence in endothelial cell growth medium (EGM-2; Cambrex Corp., East Rutherford, NJ, USA) at 371C, 5% CO 2 . siRNAs were mixed with 100 ml Opti-MEM (Invitrogen, Carlsbad, CA, USA) without serum to a concentration of 125 nM. The siRNA solution was then combined 1:1 with a diluted solution of Lipofectamine 2000 (LF2K; Invitrogen, Carlsbad CA, USA), gently mixed, and incubated for 30 min at room temperature to allow formation of siRNA/LF2K complexes. The diluted LF2K was prepared by mixing 2.0 ml LF2K and 98 ml Opti-MEM. For transfection, the EGM-2 was aspirated from the cells and replaced with 200 ml of Opti-MEM without serum. siRNA/LF2K complexes (50 ml/well) were added to treatment wells for a final concentration of 12.5 nM, mixed gently, and plates were incubated at 371C, 5% CO 2 . After 4 h, the transfection medium was replaced with 200 ml EGM-2 and plates were incubated at 371C, 5% CO 2 for an additional 20 h. Transfections were performed in triplicate.
At 24 h after addition of siRNA to cells, total RNA was isolated with the Invitek Inviscreen RNA HTS 96-Kit/C (Invitek, Berlin, Germany) using the manufacturer's instructions. Quantitative RT-PCR was performed in ABI Prism 7000 or 7500 Sequence Detectors (Applied Biosystems, Foster City, CA, USA) using a SuperScript III Platinum One-Step qRT-PCR System and RNAout Ribonuclease Inhibitor (Invitrogen, Carlsbad, CA, USA) to measure vegfr1 or vegfr2 mRNA and compare it to GAPDH mRNA levels for normalization. Reactions contained 5 ml RNA in 50 ml. Primers used for vegfr1 Testing Sirna-027 activity in a luciferase reporter/HeLa cell culture system A luciferase reporter plasmid was made by inserting a fragment of the human vegfr1 gene (nucleotides 326-403) between the XhoI and NotI sites of the psiCHECK-2t luciferase reporter plasmid (Promega, Madison, WI, USA). Ligation into this site placed the vegfr1 target sequence in the 3 0 -untranslated region of the Renilla luciferase gene, while the Firefly luciferase control gene in the psiCHECK-2 plasmid was unaltered. The insertion was confirmed by sequencing in both directions.
In all, 15 000 HeLa S3 cells were plated in each well of a Costar 3603 black 96-well plate (Corning Incorporated, Corning, NY, USA) in 75 ml Iscove's Modified Dulbecco's Medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% bovine calf serum (Hyclone, Logan, UT, USA). Plates were incubated overnight at 371C (5% CO 2 ). The reporter plasmid and siRNA were cotransfected into HeLa cells using LF2K. Each well received 50 ml of OPTI-MEM (Invitrogen, Carlsbad, CA, USA) containing 100 ng of reporter plasmid, 0.5 ml LF2K, and siRNA (0.005-5 nM) in a final volume of 125 ml. Transfections were performed in triplicate. Following transfection, cells were incubated as above for approximately 17 h. Renilla and Firefly luciferase activities were determined using Dual-Glo luciferase reagents (Promega, Madison, WI, USA) according to the manufacturer's instructions. Data were acquired on a Luminoskan Ascent luminometer (Thermo Labsystems, Helsinki, Finland). The ratio of Renilla:Firefly luciferase activity was normalized to that observed in HeLa cells cotransfected with a control siRNA and the reporter plasmid. The IC 50 was determined using Kaleidograph software (Synergy Software, Reading, PA, USA).
Testing of Sirna-027 activity in HeLa cell extracts
HeLa cytosol was prepared as described previously. 21 A transcript of human vegfr1 (GenBank Accession number NM_002019, nucleotides 313-415) was produced by T7 transcription from a DNA template 22 and 5 0 -end labeled using guanylyl transferase (Ambion, Austin, TX, USA) and a-32 P-GTP (Perkin-Elmer, Boston, MA, USA). Reactions including HeLa cell extract, 32 P-labeled vegfr1 RNA target, and 100 nM Sirna-027 were assembled in 50 ml by the method of Martinez and Tuschl. 21 Reactions were incubated at 371C and aliquots were quenched into two volumes of stop buffer (7 M urea, 1 Â TBE, xylene cyanol, bromophenol blue, pH 7) at 30, 60, 90, or 120 min, denatured for 5 min at 951C, and resolved on a 12% denaturing polyacrylamide gel with appropriate markers. To generate RNA size markers, the 32 P-labeled transcript was subjected to RNase T 1 digestion under denaturing conditions. 23 An RNA size ladder was generated by alkaline hydrolysis of the 32 P-labeled transcript. 24 The gel was dried and exposed to a phosphorimager screen. Results were visualized with a Molecular Dynamics Storm 860 phosphorimager and analyzed using ImageQuant (Molecular Dynamics, Piscataway, NJ, USA).
Assessment of distribution of siRNA in the retina after intravitreous or periocular injections
Mice were anesthetized and given an intravitreous injection of 1 ml or a periocular injection of 5 ml of PBS containing 5 mg/ml BrdU-labeled Sirna-027. Mice were euthanized at several different time points after injection and eyes were frozen in optimal cutting temperature embedding compound (OCT; Miles Diagnostics, Elkhart, IN, USA). Frozen sections (10 mm) were fixed in 4% paraformaldehyde, and incubated for 2 h in a 1:50 dilution of a rat antibody that specifically recognizes BrdU (Serotec, Oxford, UK) in 0.05 M Tris-buffered saline (TBS), pH 7.6. Slides were washed and incubated in mouse anti-rat IgG conjugated to biotin (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) for 90 min at room temperature. Slides were washed and incubated with 1:100 avidin D coupled to horseradish peroxidase (Vector Laboratories, Burlingame, CA, USA) for 45 min. After washing with 0.05 M TBS, slides were incubated with 3,3 0 -diaminobenzidine tetrahydrochloride dihydrate to give a brown reaction product. The sections were covered with a standard glass coverslip and examined by light microscopy.
Mice with oxygen-induced ischemic retinopathy
Ischemic retinopathy was produced by a previously described method. 25 At postnatal day (P) 7, mice were placed in 7573% oxygen for 5 days and then returned to room air at P12. Treatments were instituted at P12 and consisted of intravitreous or periocular injection of Sirna-027 in one eye and injection of vehicle (PBS) or inverted control siRNA in the fellow eye. For analysis of vegfr1 mRNA after siRNA treatment, mice were either given a 1 ml intravitreous injection containing 3 mg of Sirna-027 or inverted control siRNA or a 5 ml periocular injection containing 7.5 mg Sirna-027 or the inverted control. Retinas were harvested on P15 or P17, respectively. For analysis of VEGFR1 protein after siRNA treatment, mice were given a 1 ml intravitreous injection containing 5 mg of Sirna-027 or inverted control siRNA. Retinas were harvested on P15. To assess retinal NV in this model, mice were treated at P12 with a 1 ml intravitreous injection containing 1 mg of Sirna-027 or inverted control siRNA. Retinal NV was measured as described below using eyes harvested on P17.
Measurement of the amount of retinal NV
Serial sections (10 mm) were cut through the entire eye, starting with sections that included the iris root on one side of the eye and proceeding to the iris root on the other side. Every tenth section, roughly 100 mm apart, was stained with biotinylated Griffonia simplicifolia lectin B4 (GSA, Vector Laboratories, Burlingame, CA, USA), which selectively binds to vascular cells. Slides were incubated in methanol/H 2 O 2 for 10 min at 41C, washed with 0.05 M TBS, pH 7.6, and incubated for 30 min in 10% normal porcine serum. Slides were incubated for 2 h at room temperature with biotinylated GSA and after rinsing with 0.05 M TBS, they were incubated with avidin coupled to peroxidase (Vector Laboratories) for 45 min at room temperature. After being washed for 10 min with 0.05 M Tris buffer, pH 7.6, slides were incubated with diaminobenzidine (Research Genetics, Huntsville, AL, USA) to give a brown reaction product, and mounted Knockdown of vegfr1 mRNA inhibits ocular neovascularization J Shen et al with Cytoseal (Stephens Scientific, Riverdale, NJ, USA). Slides were examined with an Axioskop microscope, and images were digitized using a 3 CCD color video camera and a frame grabber. Image-Pro Plus software was used to delineate GSA-stained cells on the surface of the retina and their area was measured. The mean of the measurements from each eye was used as a single experimental value.
Measurement of retinal vegfr1 mRNA
Retinas were dissected and total RNA was isolated using an RNeasy kit (Qiagen Inc., Chatsworth, CA, USA). After quantification of RNA concentration using Gene SpecIII (Hitachi, Japan), 1 mg was treated with DNase I (Ambion Inc., Austin, TX, USA) to remove any contaminating genomic DNA and cDNA was synthesized with RT (SuperScript II; Life Technologies, Gaithersburg, MD, USA) and 5.0 mM oligo-d(T) primer. Samples of cDNA were aliquoted and stored at À801C. For visualization of mRNA, amplification was performed using primers specific for vegfr1 mRNA: 5 0 -AAG ATG CCA GCC GAA GGA GA-3 0 (forward) and 5 0 -GGC TCG GCA CCT ATA GA CA-3 0 (reverse). Titrations were determined to ensure that PCR was performed in the linear range of amplification. Mouse S16 ribosomal protein primers, 5 0 -CAC TGC AAA CGG GGA AAT GG-3 0 (forward) and 5 0 -TGA GAT GGA CTG TCG GAT GG-3 0 (reverse), were used to provide an internal control for the amount of template in the PCR reactions. In all, 20 mL of PCR product was loaded and electrophoresed on a 1% agarose gel and visualized using ethidium bromide. The gel was photographed using a Kodak Gel Logic 200 gel imaging system (Rochester, NY, USA).
To quantify levels of vegfr1 mRNA, quantitative RT-PCR was performed and analyzed using the SYBR Green I format on the LightCycler rapid thermal cycler system (Roche Molecular Biochemicals, Indianapolis, IN, USA). Reactions were performed in a 20-ml volume using the FastStart Master SYBR Green I reaction mix (Roche Molecular Biochemicals) with 0.5 mM primers and MgCl 2 concentration optimized between 2 and 5 mM. Cyclophilin A was used as a standard for normalization. The sequences of the PCR primer pairs used were: VEGFR1, 5 0 -CTG CCC TAT GAT GCC AGC AA-3 0 (forward) and 5 0 -ACG CTT CGG TCT TCA GGG AA3 0 (reverse); cyclophilin A, 5 0 -CAG ACG CCA CTG TCG CTT T-3 0 (forward) and 5 0 -TGT CTT TGG AAC TTT GTC TGC AA-3 0 (reverse). Murine vegfr1 and cyclophilin A mRNA were amplified with Pfu Taq polymerase (Stratagene, La Jolla, CA, USA), PCR products were purified with a gel extraction kit (Qiagen, Chatsworth, CA, USA), and mRNA copy numbers were calculated according to the Roche quantification technique manual. Standard curves for each gene were plotted with quantified cDNA template during each RT-PCR reaction. Target gene mRNA copy number was normalized to 10 6 copies of cyclophilin A.
Enzyme-linked immunoadsorbent assays
The retinas were removed and placed in 200 ml lysis buffer (50 ml 1 M Tris-HCl (pH 7.4), 50 ml 10% sodium dodecyl sulfate, 5 ml 100 nM phenylmethaneculfonyl and 5 ml sterilized, de-ionized water). Retinas were homogenized by pipetting, sonicated at 41C for 5 s, and centrifuged at 13 K for 5 min at 41C. The pellet was discarded and the supernatant was transferred to a fresh tube. The protein concentration of supernatants was measured using a Bio-Rad Protein Assay Kit (Bio-Rad, Hercules, CA, USA). ELISAs were performed using the Quantikine VEGFR1 assay kit (R & D Systems, Minneapolis, MN, USA) using the manufacturer's instructions. Serial dilutions of recombinant VEGFR1 were assayed to generate a standard curve with the limit of detection at 125 pg/ml.
Model of laser-induced CNV
CNV was generated by modification of a previously described technique. 26 Briefly, 4-5-week-old female C57BL/6J mice were anesthetized and the pupils were dilated with 1% tropicamide. Three burns of 532 nm diode laser photocoagulation (75 mm spot size, 0.1 s duration, 120 mW) were delivered to each retina using the slit lamp delivery system of an OcuLight GL Photocoagulator (Iridex, Mountain View, CA, USA) and a hand-held cover slide as a contact lens. Burns were performed in the 9, 12, and 3 o'clock positions of the posterior pole of the retina. Production of a bubble at the time of laser, which indicates rupture of Bruch's membrane, is an important factor in obtaining CNV, 26 so only burns in which a bubble was produced were included in the study. Mice were treated with Sirna-027 by intravitreous injections on the day of laser (day 1) and day 7 or periocular injections on days 1, 4, 7, 10, and 13. For intravitreous injections, mice were given 0.5 or 1.5 mg of Sirna-027 in one eye and an equivalent amount of inverted control siRNA or vehicle in the fellow eye. For each periocular injection, mice were given 7.5 mg of Sirna-027 in one eye and inverted siRNA in the fellow eye. Mice were euthanized 14 days after laser for measurement of the area of CNV at Bruch's membrane rupture sites.
Measurement of CNV area
The area of CNV at Bruch's membrane rupture sites was measured in choroidal flat mounts. 27 Mice were anesthetized and perfused with 1 ml of PBS containing 50 mg/ ml of fluorescein-labeled dextran (2x10 6 average mw, Sigma, St Louis, MO, USA) as described previously. 28 The eyes were removed and fixed for 1 h in 10% phosphate-buffered formalin. The cornea and lens were removed and the entire retina was carefully dissected from the eyecup. Radial cuts (4-7, average 5) were made from the edge to the equator and the eyecup was flat mounted in Aquamount with the sclera facing down. Flat mounts were examined by fluorescence microscopy on an Axioskop microscope (Zeiss, Thornwood, NY, USA) and images were digitized using a three-color CCD video camera (IK-TU40A, Toshiba, Tokyo, Japan) and a frame grabber. Image-Pro Plus software (Media Cybernetics, Silver Spring, MD, USA) was used to measure the total area of hyperfluorescence associated with each burn, corresponding to the total fibrovascular scar. The areas within each eye were averaged to give one experimental value per eye for plotting the areas in the figures.
Statistical analyses
Data are presented graphically as mean+s.e.m. For in vivo studies, comparisons between Sirna-027-treated and control-treated fellow eyes were analyzed using a Knockdown of vegfr1 mRNA inhibits ocular neovascularization J Shen et al two-way analysis of variance or paired t-tests. Each animal served as its own control. For in vitro studies, a one-way analysis of variance or unpaired t-tests were used for comparisons among groups. Data were logtransformed for analysis. P-values were not adjusted for multiple comparisons; all P-values are two-tailed.
